The abstract is read at the publisher; the summary is JClub's.
Targeting thymine DNA glycosylase (TDG) with the covalent inhibitor C-271 induces synthetic lethality in p53-deficient cancers, suppressing tumors and enhancing antitumor immunity.
- Why it matters: The therapeutic mechanisms for TDG in cancer progression are unclear, limiting rational development of TDG-targeted treatments, especially for p53-deficient settings.
- What they did: The authors developed C-271, a first-in-class small-molecule that covalently binds TDG and disrupts its DNA-binding capability, then tested its effects on p53-deficient cancer cells and tumors.
- The result: In p53-deficient cancer cells, TDG inhibition downregulates DHX9, causing aberrant dsRNA accumulation that activates the RIG-I/MDA5-MAVS sensing pathway, leading to tumor suppression and enhanced antitumor immunity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.